623 related articles for article (PubMed ID: 30073930)
1. Antibody-Drug Conjugates: A Review on the Epitome of Targeted Anti- Cancer Therapy.
Hasan M; Alam S; Poddar SK
Curr Clin Pharmacol; 2018; 13(4):236-251. PubMed ID: 30073930
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates: A promising breakthrough in cancer therapy.
Parit S; Manchare A; Gholap AD; Mundhe P; Hatvate N; Rojekar S; Patravale V
Int J Pharm; 2024 Jun; 659():124211. PubMed ID: 38750981
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.
Malik P; Phipps C; Edginton A; Blay J
Pharm Res; 2017 Dec; 34(12):2579-2595. PubMed ID: 28924691
[TBL] [Abstract][Full Text] [Related]
4. [Novel Chemical Linkers for Next-generation Antibody-drug Conjugates(ADCs)].
Tsuchikama K
Yakugaku Zasshi; 2019; 139(2):209-219. PubMed ID: 30713230
[TBL] [Abstract][Full Text] [Related]
5. Antibody-targeted drugs and drug resistance--challenges and solutions.
Shefet-Carasso L; Benhar I
Drug Resist Updat; 2015 Jan; 18():36-46. PubMed ID: 25476546
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates- stability and formulation.
Duerr C; Friess W
Eur J Pharm Biopharm; 2019 Jun; 139():168-176. PubMed ID: 30940541
[TBL] [Abstract][Full Text] [Related]
7. Current methods for the synthesis of homogeneous antibody-drug conjugates.
Sochaj AM; Świderska KW; Otlewski J
Biotechnol Adv; 2015 Nov; 33(6 Pt 1):775-84. PubMed ID: 25981886
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: recent advances in conjugation and linker chemistries.
Tsuchikama K; An Z
Protein Cell; 2018 Jan; 9(1):33-46. PubMed ID: 27743348
[TBL] [Abstract][Full Text] [Related]
9. Antibody-drug conjugates: a mini-review. The synopsis of two approved medicines.
Papachristos A; Pippa N; Demetzos C; Sivolapenko G
Drug Deliv; 2016 Jun; 23(5):1662-6. PubMed ID: 25625494
[TBL] [Abstract][Full Text] [Related]
10. Antibody Drug Conjugates for Cancer Therapy.
Polakis P
Pharmacol Rev; 2016 Jan; 68(1):3-19. PubMed ID: 26589413
[TBL] [Abstract][Full Text] [Related]
11. Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.
Chen H; Lin Z; Arnst KE; Miller DD; Li W
Molecules; 2017 Aug; 22(8):. PubMed ID: 28763044
[TBL] [Abstract][Full Text] [Related]
12. ADCs, as Novel Revolutionary Weapons for Providing a Step Forward in Targeted Therapy of Malignancies.
Amani N; Dorkoosh FA; Mobedi H
Curr Drug Deliv; 2020; 17(1):23-51. PubMed ID: 31755387
[TBL] [Abstract][Full Text] [Related]
13. Prospects and progress of antibody-drug conjugates in solid tumor therapies.
Govindan SV; Sharkey RM; Goldenberg DM
Expert Opin Biol Ther; 2016 Jul; 16(7):883-93. PubMed ID: 27045979
[TBL] [Abstract][Full Text] [Related]
14. Antibody-drug conjugates in cancer therapy.
Sievers EL; Senter PD
Annu Rev Med; 2013; 64():15-29. PubMed ID: 23043493
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates: Current status and future perspectives.
Gébleux R; Casi G
Pharmacol Ther; 2016 Nov; 167():48-59. PubMed ID: 27492898
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
[TBL] [Abstract][Full Text] [Related]
17. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates and bispecific antibodies targeting cancers: applications of click chemistry.
Hong Y; Nam SM; Moon A
Arch Pharm Res; 2023 Mar; 46(3):131-148. PubMed ID: 36877356
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic and Immunological Considerations for Expanding the Therapeutic Window of Next-Generation Antibody-Drug Conjugates.
Khera E; Thurber GM
BioDrugs; 2018 Oct; 32(5):465-480. PubMed ID: 30132210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
